Endpoints News – The biopharma world is here

SUBSCRIBE

top stories

FDA asks why Novartis took two months to launch formal internal probe, after AveXis flagged data manipulation

2 days ago

Why would Amgen want to buy Alexion? Analysts call hotly rumored takeover unlikely, but seize the moment

2 days ago

GSK's Hal Barron heralds their second positive pivotal for crucial anti-BCMA therapy, pointing to a push for quick ...

2 days ago

Latest

Most read

Prisoner #87850-053 does not get to add drug developer to his list of credits

3 days ago

Pfizer, Astellas win priority review for Xtandi sNDA; Hemispherx changes its name

2 days ago

Ignyta founder boosts team at his new cancer startup; Cytomx CMO hits the exit

2 days ago

Building on successful PD-1 pact, Eli Lilly licenses diabetes drug to Chinese partners at Innovent

2 days ago

see latest stream

People

Sir Andrew Dillon, NICE's first — and only — chief executive to step down next year

3 days ago

MHRA to land a new interim chief executive ahead of Brexit

4 days ago

AveXis scientific founder fires back at Novartis CEO Vas Narasimhan, 'categorically denies any wrongdoing'

6 days ago

Startups

Versant-backed Chinook gets a $65M launch round for its discovery quest in a resurgent kidney field

3 days ago

Finch grabs a $53M round designed to take their ‘breakthrough’ microbiome treatment through a potentially pivotal ...

3 days ago

Johns Hopkins scientists raise $137M megaround for a trio of spinouts looking to tackle Alzheimer’s, Parkinson’s ...

Last week

Deals

Vienna-based vaccine developer Themis signs pact with Merck for 'blockbuster indication'

3 days ago

Elanco to buy Bayer's animal health business for $7.6B, as dealmaking gathers steam in the sector

5 days ago

On the cusp of PhI, Angelman-focused biotech scores potential buyout deal from Ultragenyx

Last week

IPOs

Fresh from $102M haul, IGM Bio pitches $100M IPO as it plots first-in-human trial of new antibodies

5 days ago

SpringWorks seeks $115M to push Pfizer drugs across finish line while Satsuma sells migraine play in $86M IPO

6 days ago

A budget biotech you likely never heard about is setting a course for Wall Street with some modest ambitions

Last week

All of the news, delivered with full-text to your inbox. For professionals discovering, developing, and marketing biopharmaceutical drugs.

SUBSCRIBE NOW

Subscribe to Endpoints News

Premium storiesSee all

Webinar: Real World Endpoints — the brave new world coming in building franchise therapies

5 days ago

Bayer’s $240M upfront for BlueRock acquisition puts them in the high rollers club for preclinical biotech buyouts

3 weeks ago

Novartis' $18.5B in M&A under Vas Narasimhan says a lot about their careful — but opportunistic — deal strategy

4 weeks ago

What makes Hal Barron tick? Look at the people he’s teaming up with at GSK

Last month

Don't missSee all

UPDATED: An emboldened AstraZeneca splurges $95M on a priority review voucher. Where do they need the FDA to hustle ...

3 days ago

Eight weeks between each HIV treatment? GSK notches PhIII win as it chases OK for long-acting regimen

3 days ago

SEC calls out little TherapeuticsMD for its insider contacts with analysts to boost share price, then halt rout

4 days ago

Pfizer is making a $500M statement today: Here’s how you become a lead player in the booming gene therapy sector

4 days ago

Peer review See all

Aug

16

Bain's Orly Mishan joins Pfizer's neuro spinout Cerevel; Oncolytic virus biotech taps SillaJen exec Helena Chaye as CEO

Aug

9

Amy Burroughs to lead Cleave Therapeutics; Cynthia Collins clinches Editas CEO job amid historic CRISPR move

Aug

2

David Apelian to steer TCR play at Pitt spinout; Third Rock scoops Illumina exec as CEO of cancer detection upstart

Jul

26

Peer Review: Rubius recruits BD chief; Epizyme hires Novartis vet as CFO

Jul

19

Seer adds ex-FDA chief Mark McClellan to the board; Hercules Capital makes it official for new CEO Scott Bluestein

R&D channel feed

4 days ago

AstraZeneca’s Imfinzi/treme combo strikes out — again — in lung cancer. Is it time for last rites?

AstraZeneca bet big on the future of their PD-L1 Imfinzi combined with the experimental CTLA-4 drug tremelimumab. But once again it’s gone down to defeat in a major Phase III study — ...

READ MORE

Amgen, Allergan biosimilar of Roche's blockbuster Rituxan clears another US pivotal study

3 days ago

MDMA, now in Phase III, shows promise as a PTSD treatment

4 days ago

latest in R&D

Clearside Biomedical predicts its uveitis drug will be rejected, after FDA requests more data

2 days ago

Futility analysis augurs defeat in pivotal trial testing of NuCana's lead drug in metastatic pancreatic cancer

4 days ago

FDA decision on Vertex's CF triple will come just ahead of planned CEO shakeup

5 days ago

An MIT spinout kills one of its ‘living therapeutics’ after flunking an early-stage study — shares routed

5 days ago

AstraZeneca's diabetes drug Farxiga helps patients with heart disease and without diabetes in landmark trial

5 days ago

see latest stories

Pharma channel feed

3 days ago

Get as much Spravato as you can, Trump orders VA while suggesting J&J should offer it to veterans for free

President Donald Trump is making good on his earlier pledge to offer Spravato, J&J’s reformulated ketamine nasal spray, to as many veterans in need, as soon as possible — however it ...

READ MORE

Novartis spinoff Nabriva finally scores its first antibiotic approval

6 days ago

I’m not perfect: Novartis chief Vas Narasimhan almost apologizes in the wake of a new crisis

6 days ago

latest in Pharma

Celgene and the scientist who championed fedratinib's rise from Sanofi's R&D graveyard win FDA OK

Last week

ICER blasts FDA, PTC and Sarepta for high prices on DMD drugs Emflaza, Exondys 51

Last week

The top 10 franchise drugs in biopharma history will earn a total of $1.4T (trillion) by 2024 — what does that tell us?

Last week

Scientist-CEO accused of improperly using confidential info from unicorn Alector

Last week

Ailing Mallinckrodt's drug for rare, life-threatening renal condition clears pivotal study

Last week

see latest stories